Kyowa Hakko’s Citicoline Obtains Novel Food Registration status in Europe
New York, NY (PRWEB) July 17, 2014 -- Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) delivered a scientific opinion on Citicoline as a novel food ingredient (NFI), concluding on October 2013 that Citicoline is safe under the proposed uses and use levels. http://www.efsa.europa.eu/it/efsajournal/doc/3421.pdf
Commission Implementing Decision 2014/423/EU of 1 July 2014 authorizing Kyowa Hakko the placing on the market of Citicoline as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council. (http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOL_2014_196_R_0006&from=EN )
Citicoline is intended to be used in food supplements in Europe aimed at adult population at a maximum level of 500 mg/day, and in foods for particular nutritional uses, specifically foods for special medical purposes, at a maximum level of 250 mg/serving, and with a maximum daily intake from these types of foods of 1,000 mg/day.
Citicoline is the generic name for CDP-choline (choline cytidine 5’-pyrophosphate), organic molecule produced endogenously and found in all living cells. Is a source of choline and precursor for the synthesis of phospholipids that are essential constituents of cell membranes, including phosphatidylcholine, phosphatidylserine and phosphatidyl-ethanolamine.
In United States, under Cognizin® brand name, Kyowa Hakko USA, Inc. has been marketing Citicoline since the early 1980’s as dietary supplement and created the trademark name in 2004, received self-affirmed Generally Recognized As Safe (GRAS) status in 2009, as food ingredient for use at levels of 250 mg per serving in such products as dietary supplements, beverages, breakfast cereals, chewing gum, pastas, hard candies, milk products, fruit juices and soft candy.
Cognizin® Citicoline is often called a “brain nutrient” because it increases levels of several important neurotransmitters including acetylcholine, dopamine and noradrenaline; helps maintain the integrity of neuronal cell membranes and increases energy production in the frontal cortex.
About Cognizin® Citicoline
A proprietary form of Citicoline, Cognizin® is a potent brain-health nutrient that’s been clinically studied to support mental energy, focus, attention and recall. Tested in human clinical trials and developed using a patented fermentation process, Cognizin® is a pure, allergen-free GRAS ingredient that’s stable and effective.
For more information on Cognizin®, go to http://www.cognizin.com
About Kyowa Hakko Europe
Kyowa Hakko Europe and Kyowa Hakko Bio Italia are the Central-North and South European sales office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. For more information visit http://www.kyowa.eu or email at finechemicals(at)kyowa(dot)it
About Kyowa Hakko USA
Kyowa Hakko USA is the North American sales office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine. For more information visit http://www.kyowa-usa.com
# # #
Karen E. Todd, RD, CSCS, HFS, Kyowa Hakko U.S.A., http://www.kyowa-usa.com, +1 (212) 319-5353 Ext: 403, [email protected]
Share this article